中國化學(601117.SH):國新投資向中化學建投轉讓公司2%股份
格隆匯7月9日丨中國化學(601117.SH)公佈,公司於2020年7月8日收到公司持股5%以上股東國新投資出具的《簡式權益變動報告書》。國新投資是中國國新控股有限責任公司的全資子公司。國新投資於2020年7月8日以大宗交易方式轉讓公司股份9866萬股給公司控股股東中國化學集團的全資子公司中化學建投,轉讓比例為公司總股本的2%。
本次交易前,中國化學集團直接及間接持有公司53.61%股份,為公司控股股東;國新投資持有公司5.68%股份,為公司持股5%以上股東。中化學建投作為公司控股股東中國化學集團的一致行動人,本次以自有資金增持中國化學股票後,中國化學集團直接及間接持有公司55.61%股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.